The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 101K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Armant, M.
Right arrow Articles by Sarfati, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armant, M.
Right arrow Articles by Sarfati, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/1999/10/1175/ $5.00
The Journal of Experimental Medicine, Volume 190, Number 8, October 18, 1999 1175-1182

Brief Definitive Report

Cd47 Ligation Selectively Downregulates Human Interleukin 12 Production

Myriam Armanta, Marie-Noëlle Avicea, Patrice Hermanna, Manuel Rubioa, Mamoru Kiniwaa, Guy Delespessea, and Marika Sarfatia

a Laboratoire Allergie, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CHUM), Campus Notre-Dame, Quebec H2L 4M1, Canada
University of Montreal, Laboratoire Allergie (M4211-K), Centre de Recherche du CHUM, Campus Notre-Dame, 1560 Sherbrooke Street East, Montreal, Quebec H2L 4M1, Canada.514-896-4753514-281-6000 ext. 6632

sarfatm{at}poste.umontreal.ca

Interleukin (IL)-12 plays a key role not only in protective innate and adaptive T helper cell type 1 (Th1) responses but also in chronic inflammatory diseases. We report here that engagement of CD47 by either monoclonal antibody, its natural ligand thrombospondin (TSP), or 4N1K (a peptide of the COOH-terminal domain of TSP selectively binding CD47) inhibits IL-12 release by monocytes. The suppression occurred after T cell–dependent or –independent stimulation of monocytes and was selective for IL-12 inasmuch as the production of tumor necrosis factor (TNF)-{alpha}, IL-1, IL-6, and granulocyte/macrophage colony-stimulating factor was not inhibited. CD47 ligation did not alter transforming growth factor (TGF)-β and IL-10 production, and the suppressive effect on IL-12 was not due to autocrine secretion of TGF-β or IL-10. The IL-12 inhibition was not mediated by Fc{gamma} receptor ligation, did not require extracellular Ca2+ influx, but was reversed by two phosphoinositide 3-kinase inhibitors (wortmannin and Ly294002). Thus, engagement of CD47 on monocytes by TSP, which transiently accumulates at the inflammatory site, is a novel and unexplored pathway to selectively downregulate IL-12 response. The pathway may be relevant in limiting the duration and intensity of the inflammatory response, and in developing novel therapeutic strategies for Th1-mediated diseases.

Key Words: CD47 • interleukin 12 • monocytes • thrombospondin

M. Armant's present address is Laboratory for Parasitic Diseases, Bldg. 4, National Institutes of Health, Bethesda, MD 20892-0425. M. Kiniwa's present address is Immunological and Cardio-Vascular Research Lab., Hanno Research Center, Taiho Pharmaceutical Company Ltd., Saitama 357, Japan.

© 1999 The Rockefeller University Press


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS